Discussion
tumours
TUMOURS, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, MICROSATELLITE INSTABILITY
We assessed three dosing schedules of a single priming dose of The patient population included in this study had molecularly unselected metastatic castration-resistant prostate cancer without genomic evidence of tumours with a high mutational burden or microsatellite instability, a setting in which responses are expected in fewer than 10% of patients given pembrolizumab alone.The combination is further supported by the favourable results from the PRINCE study,The current study design differs substantially from the phase 3 VISION study.The optimal dose and schedule for immunogenic priming with There is substantial heterogeneity in PSMA expression and uptake on PSMA PET in the metastatic castration-resistant prostate cancer setting, which narrows the scope of who might benefit from targeted radioligand therapy.Our study had limitations including the non-randomised design, which precludes the ability to ascertain the individual contribution of pembrolizumab and A phase 2 study is planned combining maintenance pembrolizumab with repeated doses of 